Foghorn Therapeutics (FHTX) Research & Development (2020 - 2025)
Historic Research & Development for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $20.0 million.
- Foghorn Therapeutics' Research & Development fell 1898.42% to $20.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.9 million, marking a year-over-year decrease of 1455.54%. This contributed to the annual value of $94.5 million for FY2024, which is 1382.18% down from last year.
- According to the latest figures from Q3 2025, Foghorn Therapeutics' Research & Development is $20.0 million, which was down 1898.42% from $21.8 million recorded in Q2 2025.
- In the past 5 years, Foghorn Therapeutics' Research & Development registered a high of $30.0 million during Q1 2023, and its lowest value of $18.6 million during Q2 2021.
- In the last 5 years, Foghorn Therapeutics' Research & Development had a median value of $24.2 million in 2023 and averaged $23.9 million.
- In the last 5 years, Foghorn Therapeutics' Research & Development surged by 6279.23% in 2021 and then crashed by 1898.42% in 2025.
- Quarter analysis of 5 years shows Foghorn Therapeutics' Research & Development stood at $22.5 million in 2021, then increased by 25.58% to $28.2 million in 2022, then dropped by 14.19% to $24.2 million in 2023, then dropped by 15.27% to $20.5 million in 2024, then decreased by 2.47% to $20.0 million in 2025.
- Its Research & Development was $20.0 million in Q3 2025, compared to $21.8 million in Q2 2025 and $21.6 million in Q1 2025.